Genentech Aims For Broad Access To Avastin In Cervical Cancer, But Needs To Figure Out How To Get There

FDA approval is fifth indication for Roche/Genentech’s Avastin. Number of cases in the U.S. is low and set to decline with better prevention, but disease is considered a major global health problem.